Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Top Cited Papers
- 1 May 2019
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 393 (10183) , 1819-1830
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2015
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRNew England Journal of Medicine, 2010
- First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic ReviewJournal of Thoracic Oncology, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Group sequential designs using a family of type I error probability spending functionsStatistics in Medicine, 1990
- Comparative analysis of two ratesStatistics in Medicine, 1985
- The Efficiency of Cox's Likelihood Function for Censored DataJournal of the American Statistical Association, 1977